Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

videos

Peter Martin, MD
Conference Coverage
Novel Advancements in Marginal Zone Lymphoma Research
10/29/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Peter Martin, MD, discusses recent data and updates in marginal zone lymphoma research.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Peter Martin, MD, discusses recent data and updates in marginal zone lymphoma research.
At the 2024 Lymphoma, Leukemia &...
10/29/2024
Lymphoma, Leukemia & Myeloma Network
Peter Martin, MD
Conference Coverage
Novel Advancements in Marginal Zone Lymphoma Research
10/29/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Peter Martin, MD, discusses recent data and updates in marginal zone lymphoma research.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Peter Martin, MD, discusses recent data and updates in marginal zone lymphoma research.
At the 2024 Lymphoma, Leukemia &...
10/29/2024
Lymphoma, Leukemia & Myeloma Network
Mark Bustoros, MD
Conference Coverage
Identifying Unmet Clinical Needs in Treating Patients With Extramedullary MM
10/28/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Mark Bustoros, MD, shares expert insight into the unmet clinical needs in targeting and treating patients with extramedullary multiple myeloma, an aggressive subtype of myeloma.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Mark Bustoros, MD, shares expert insight into the unmet clinical needs in targeting and treating patients with extramedullary multiple myeloma, an aggressive subtype of myeloma.
At the 2024 Lymphoma, Leukemia &...
10/28/2024
Lymphoma, Leukemia & Myeloma Network
Mark Bustoros, MD
Conference Coverage
Identifying Unmet Clinical Needs in Treating Patients With Extramedullary MM
10/28/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Mark Bustoros, MD, shares expert insight into the unmet clinical needs in targeting and treating patients with extramedullary multiple myeloma, an aggressive subtype of myeloma.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Mark Bustoros, MD, shares expert insight into the unmet clinical needs in targeting and treating patients with extramedullary multiple myeloma, an aggressive subtype of myeloma.
At the 2024 Lymphoma, Leukemia &...
10/28/2024
Lymphoma, Leukemia & Myeloma Network
Bruno Paiva, PhD
Conference Coverage
Exploring the Immune Microenvironment in Multiple Myeloma Treatment
10/25/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Bruno Paiva, PhD, shared expert insight into the immune determinants of response and resistance among patients with multiple myeloma, highlighting the need to bring immune biomarkers into the...
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Bruno Paiva, PhD, shared expert insight into the immune determinants of response and resistance among patients with multiple myeloma, highlighting the need to bring immune biomarkers into the...
At the 2024 Lymphoma, Leukemia &...
10/25/2024
Lymphoma, Leukemia & Myeloma Network
Bruno Paiva, PhD
Conference Coverage
Exploring the Immune Microenvironment in Multiple Myeloma Treatment
10/25/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Bruno Paiva, PhD, shared expert insight into the immune determinants of response and resistance among patients with multiple myeloma, highlighting the need to bring immune biomarkers into the...
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Bruno Paiva, PhD, shared expert insight into the immune determinants of response and resistance among patients with multiple myeloma, highlighting the need to bring immune biomarkers into the...
At the 2024 Lymphoma, Leukemia &...
10/25/2024
Lymphoma, Leukemia & Myeloma Network
Jonathan Canaani, MD
Conference Coverage
Advances in Risk Stratification and Treatment for Patients With AML
10/24/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Jonathan Canaani, MD, discusses advancements in risk stratification and prognosis among patients with acute myeloid leukemia.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Jonathan Canaani, MD, discusses advancements in risk stratification and prognosis among patients with acute myeloid leukemia.
At the 2024 Lymphoma, Leukemia &...
10/24/2024
Oncology
Jonathan Canaani, MD
Conference Coverage
Advances in Risk Stratification and Treatment for Patients With AML
10/24/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Jonathan Canaani, MD, discusses advancements in risk stratification and prognosis among patients with acute myeloid leukemia.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Jonathan Canaani, MD, discusses advancements in risk stratification and prognosis among patients with acute myeloid leukemia.
At the 2024 Lymphoma, Leukemia &...
10/24/2024
Oncology
Joseph Mikhael, MD
Conference Coverage
Treatment Options for When Immune Therapies Fail Among Patients With R/R MM
10/24/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment possibilities for patients with 
R/R multiple myeloma when immune therapies, such as antibody drug conjugates, CAR T-cell therapy, and bispecific...
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment possibilities for patients with 
R/R multiple myeloma when immune therapies, such as antibody drug conjugates, CAR T-cell therapy, and bispecific...
At the 2024 Lymphoma, Leukemia &...
10/24/2024
Lymphoma, Leukemia & Myeloma Network
Joseph Mikhael, MD
Conference Coverage
Treatment Options for When Immune Therapies Fail Among Patients With R/R MM
10/24/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment possibilities for patients with 
R/R multiple myeloma when immune therapies, such as antibody drug conjugates, CAR T-cell therapy, and bispecific...
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment possibilities for patients with 
R/R multiple myeloma when immune therapies, such as antibody drug conjugates, CAR T-cell therapy, and bispecific...
At the 2024 Lymphoma, Leukemia &...
10/24/2024
Lymphoma, Leukemia & Myeloma Network

Advertisement

About

For nearly 2 decades, the Lymphoma, Leukemia & Myeloma Congress (formerly the Lymphoma & Myeloma Congress) has been recognized around the world as the most respected forum for industry-leading hematologic research.

It’s where interdisciplinary specialists convene to explore the controversial and the complex, the emerging and the exciting, and discuss, debate, and discover along the way.

This program features 4 days of comprehensive learning as we analyze emerging data, discover innovative treatment methods, and get a glimpse into the future of lymphoma, myeloma, and leukemia disorders.

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use